Is GILD or AMGN more profitable?

Amgen has a net margin of 22.95% compared to Gilead Sciences' net margin of -10.64%. Amgen's return on equity of 124.14% beat Gilead Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Gilead Sciences -10.64% -2.11% -0.75% Amgen 22.95% 124.14% 13.18%

Does the media refer more to GILD or AMGN?

In the previous week, Amgen had 1 more articles in the media than Gilead Sciences. MarketBeat recorded 54 mentions for Amgen and 53 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 1.23 beat Amgen's score of 1.02 indicating that Gilead Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gilead Sciences 34 Very Positive mention(s) 5 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Amgen 32 Very Positive mention(s) 2 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 5 Very Negative mention(s) Positive

Does the media refer more to LGND or GILD?

In the previous week, Gilead Sciences had 50 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 53 mentions for Gilead Sciences and 3 mentions for Ligand Pharmaceuticals. Gilead Sciences' average media sentiment score of 1.23 beat Ligand Pharmaceuticals' score of 0.90 indicating that Gilead Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gilead Sciences 34 Very Positive mention(s) 5 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Is MRNA or GILD more profitable?

Gilead Sciences has a net margin of -10.64% compared to Moderna's net margin of -141.43%. Gilead Sciences' return on equity of -2.11% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -141.43% -28.30% -19.39% Gilead Sciences -10.64% -2.11% -0.75%

Does the media favor MRNA or GILD?

In the previous week, Moderna had 23 more articles in the media than Gilead Sciences. MarketBeat recorded 76 mentions for Moderna and 53 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 1.23 beat Moderna's score of 0.57 indicating that Gilead Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 29 Very Positive mention(s) 16 Positive mention(s) 13 Neutral mention(s) 3 Negative mention(s) 5 Very Negative mention(s) Positive Gilead Sciences 34 Very Positive mention(s) 5 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer GILD or REGN?

In the previous week, Gilead Sciences had 5 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 53 mentions for Gilead Sciences and 48 mentions for Regeneron Pharmaceuticals. Gilead Sciences' average media sentiment score of 1.23 beat Regeneron Pharmaceuticals' score of 0.77 indicating that Gilead Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gilead Sciences 34 Very Positive mention(s) 5 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Regeneron Pharmaceuticals 23 Very Positive mention(s) 3 Positive mention(s) 17 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Does the media prefer GILD or VIR?

In the previous week, Gilead Sciences had 46 more articles in the media than Vir Biotechnology. MarketBeat recorded 53 mentions for Gilead Sciences and 7 mentions for Vir Biotechnology. Gilead Sciences' average media sentiment score of 1.23 beat Vir Biotechnology's score of 1.07 indicating that Gilead Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gilead Sciences 34 Very Positive mention(s) 5 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Vir Biotechnology 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Gilead Sciences (GILD) Competitors

$150.60 -0.63 (-0.41%)

As of 02:30 PM Eastern

Compare

GILD vs. AMGN, LGND, MRNA, REGN, and VIR

Should you buy Gilead Sciences stock or one of its competitors? Gilead Sciences's main competitors and comparable companies include Amgen (AMGN), Ligand Pharmaceuticals (LGND), Moderna (MRNA), Regeneron Pharmaceuticals (REGN), and Vir Biotechnology (VIR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Gilead Sciences compare to Amgen?

Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Gilead Sciences presently has a consensus target price of $158.04, indicating a potential upside of 4.93%. Amgen has a consensus target price of $381.68, indicating a potential downside of 12.61%. Given Gilead Sciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Gilead Sciences is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0 Sell rating(s)	5 Hold rating(s)	24 Buy rating(s)	1 Strong Buy rating(s)	2.87
Amgen	3 Sell rating(s)	12 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.43

Gilead Sciences has higher earnings, but lower revenue than Amgen. Gilead Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$30.46B	6.13	$8.51B	-$2.67	N/A
Amgen	$38.10B	6.20	$7.71B	$16.09	27.14

Gilead Sciences has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market. Comparatively, Amgen has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market.

In the previous week, Amgen had 1 more articles in the media than Gilead Sciences. MarketBeat recorded 54 mentions for Amgen and 53 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 1.23 beat Amgen's score of 1.02 indicating that Gilead Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gilead Sciences	34 Very Positive mention(s)	5 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Amgen	32 Very Positive mention(s)	2 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	5 Very Negative mention(s)	Positive

Amgen has a net margin of 22.95% compared to Gilead Sciences' net margin of -10.64%. Amgen's return on equity of 124.14% beat Gilead Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	-10.64%	-2.11%	-0.75%
Amgen	22.95%	124.14%	13.18%

83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by company insiders. Comparatively, 0.9% of Amgen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.2%. Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.3%. Gilead Sciences pays out -122.8% of its earnings in the form of a dividend. Amgen pays out 62.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Gilead Sciences has increased its dividend for 10 consecutive years and Amgen has increased its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Amgen beats Gilead Sciences on 12 of the 19 factors compared between the two stocks.

How does Gilead Sciences compare to Ligand Pharmaceuticals?

Ligand Pharmaceuticals (NASDAQ:LGND) and Gilead Sciences (NASDAQ:GILD) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

Ligand Pharmaceuticals has a net margin of 67.88% compared to Gilead Sciences' net margin of -10.64%. Ligand Pharmaceuticals' return on equity of 20.06% beat Gilead Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	67.88%	20.06%	11.68%
Gilead Sciences	-10.64%	-2.11%	-0.75%

Ligand Pharmaceuticals has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.33, meaning that its share price is 67% less volatile than the broader market.

Gilead Sciences has higher revenue and earnings than Ligand Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$268.09M	21.40	$124.45M	$9.35	30.77
Gilead Sciences	$30.46B	6.13	$8.51B	-$2.67	N/A

Ligand Pharmaceuticals presently has a consensus target price of $335.75, suggesting a potential upside of 16.71%. Gilead Sciences has a consensus target price of $158.04, suggesting a potential upside of 4.93%. Given Ligand Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Ligand Pharmaceuticals is more favorable than Gilead Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00
Gilead Sciences	0 Sell rating(s)	5 Hold rating(s)	24 Buy rating(s)	1 Strong Buy rating(s)	2.87

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 5.6% of Ligand Pharmaceuticals shares are held by insiders. Comparatively, 0.3% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Gilead Sciences had 50 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 53 mentions for Gilead Sciences and 3 mentions for Ligand Pharmaceuticals. Gilead Sciences' average media sentiment score of 1.23 beat Ligand Pharmaceuticals' score of 0.90 indicating that Gilead Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gilead Sciences	34 Very Positive mention(s)	5 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Ligand Pharmaceuticals beats Gilead Sciences on 11 of the 17 factors compared between the two stocks.

How does Gilead Sciences compare to Moderna?

Moderna (NASDAQ:MRNA) and Gilead Sciences (NASDAQ:GILD) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

Moderna presently has a consensus target price of $76.72, indicating a potential downside of 47.60%. Gilead Sciences has a consensus target price of $158.04, indicating a potential upside of 4.93%. Given Gilead Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Gilead Sciences is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08
Gilead Sciences	0 Sell rating(s)	5 Hold rating(s)	24 Buy rating(s)	1 Strong Buy rating(s)	2.87

Moderna has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market.

In the previous week, Moderna had 23 more articles in the media than Gilead Sciences. MarketBeat recorded 76 mentions for Moderna and 53 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 1.23 beat Moderna's score of 0.57 indicating that Gilead Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	29 Very Positive mention(s)	16 Positive mention(s)	13 Neutral mention(s)	3 Negative mention(s)	5 Very Negative mention(s)	Positive
Gilead Sciences	34 Very Positive mention(s)	5 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Gilead Sciences has a net margin of -10.64% compared to Moderna's net margin of -141.43%. Gilead Sciences' return on equity of -2.11% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
Gilead Sciences	-10.64%	-2.11%	-0.75%

75.3% of Moderna shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 10.8% of Moderna shares are owned by company insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Gilead Sciences has higher revenue and earnings than Moderna. Gilead Sciences is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	30.07	-$2.82B	-$7.99	N/A
Gilead Sciences	$30.46B	6.13	$8.51B	-$2.67	N/A

Summary

Gilead Sciences beats Moderna on 12 of the 17 factors compared between the two stocks.

How does Gilead Sciences compare to Regeneron Pharmaceuticals?

Gilead Sciences (NASDAQ:GILD) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

In the previous week, Gilead Sciences had 5 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 53 mentions for Gilead Sciences and 48 mentions for Regeneron Pharmaceuticals. Gilead Sciences' average media sentiment score of 1.23 beat Regeneron Pharmaceuticals' score of 0.77 indicating that Gilead Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gilead Sciences	34 Very Positive mention(s)	5 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Regeneron Pharmaceuticals	23 Very Positive mention(s)	3 Positive mention(s)	17 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.2%. Regeneron Pharmaceuticals pays an annual dividend of $3.76 per share and has a dividend yield of 0.5%. Gilead Sciences pays out -122.8% of its earnings in the form of a dividend. Regeneron Pharmaceuticals pays out 9.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Gilead Sciences has increased its dividend for 10 consecutive years. Gilead Sciences is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Gilead Sciences has higher revenue and earnings than Regeneron Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$30.46B	6.13	$8.51B	-$2.67	N/A
Regeneron Pharmaceuticals	$14.34B	5.97	$4.50B	$40.46	20.57

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Gilead Sciences' net margin of -10.64%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Gilead Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	-10.64%	-2.11%	-0.75%
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%

Gilead Sciences has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.2, indicating that its share price is 80% less volatile than the broader market.

Gilead Sciences presently has a consensus target price of $158.04, suggesting a potential upside of 4.93%. Regeneron Pharmaceuticals has a consensus target price of $800.36, suggesting a potential downside of 3.81%. Given Gilead Sciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Gilead Sciences is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0 Sell rating(s)	5 Hold rating(s)	24 Buy rating(s)	1 Strong Buy rating(s)	2.87
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.58

Summary

Gilead Sciences beats Regeneron Pharmaceuticals on 14 of the 20 factors compared between the two stocks.

How does Gilead Sciences compare to Vir Biotechnology?

Gilead Sciences (NASDAQ:GILD) and Vir Biotechnology (NASDAQ:VIR) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Gilead Sciences presently has a consensus target price of $158.04, indicating a potential upside of 4.93%. Vir Biotechnology has a consensus target price of $21.57, indicating a potential upside of 87.06%. Given Vir Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe Vir Biotechnology is more favorable than Gilead Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0 Sell rating(s)	5 Hold rating(s)	24 Buy rating(s)	1 Strong Buy rating(s)	2.87
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by insiders. Comparatively, 2.9% of Vir Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Gilead Sciences has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market.

Gilead Sciences has higher revenue and earnings than Vir Biotechnology. Gilead Sciences is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$30.46B	6.13	$8.51B	-$2.67	N/A
Vir Biotechnology	$68.56M	28.46	-$437.99M	-$1.86	N/A

Gilead Sciences has a net margin of -10.64% compared to Vir Biotechnology's net margin of -638.88%. Gilead Sciences' return on equity of -2.11% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	-10.64%	-2.11%	-0.75%
Vir Biotechnology	-638.88%	-29.99%	-23.62%

In the previous week, Gilead Sciences had 46 more articles in the media than Vir Biotechnology. MarketBeat recorded 53 mentions for Gilead Sciences and 7 mentions for Vir Biotechnology. Gilead Sciences' average media sentiment score of 1.23 beat Vir Biotechnology's score of 1.07 indicating that Gilead Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gilead Sciences	34 Very Positive mention(s)	5 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Vir Biotechnology	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Gilead Sciences beats Vir Biotechnology on 9 of the 16 factors compared between the two stocks.

Get Gilead Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GILD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GILD vs. The Competition

Export

Metric	Gilead Sciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$187.04B	$3.99B	$7.18B	$12.86B
Dividend Yield	2.19%	3.60%	2.53%	8.57%
P/E Ratio	-56.50	12.74	272.98	25.36
Price / Sales	6.13	1,329.02	620.63	98.85
Price / Cash	14.29	106.87	77.82	52.27
Price / Book	15.90	16.16	12.89	6.18
Net Income	$8.51B	-$22.76M	$3.47B	$349.63M
7 Day Performance	3.39%	1.08%	1.18%	-0.13%
1 Month Performance	11.36%	8.93%	5.74%	0.73%
1 Year Performance	33.56%	53.04%	25.71%	15.38%

Gilead Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GILD Gilead Sciences	3.7478 of 5 stars	$150.62 -0.4%	$158.04 +4.9%	+33.8%	$187.04B	$30.46B	N/A	17,000	Trending News Insider Trade Analyst Revision
AMGN Amgen	4.2152 of 5 stars	$443.84 +1.0%	$380.43 -14.3%	+56.5%	$239.95B	$36.75B	27.58	31,500	Positive News Analyst Forecast Analyst Revision
LGND Ligand Pharmaceuticals	3.8782 of 5 stars	$280.18 -2.1%	$335.75 +19.8%	+74.0%	$5.59B	$268.09M	29.97	80
MRNA Moderna	1.4814 of 5 stars	$138.89 -4.3%	$74.31 -46.5%	+519.0%	$55.45B	$2.21B	N/A	4,700	Trending News Analyst Downgrade Insider Trade Options Volume Analyst Revision Gap Up High Trading Volume
REGN Regeneron Pharmaceuticals	4.0916 of 5 stars	$828.50 -0.7%	$801.70 -3.2%	+49.6%	$85.30B	$14.34B	20.48	15,410	Trending News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GILD) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gilead Sciences (GILD) Competitors

GILD vs. AMGN, LGND, MRNA, REGN, and VIR

How does Gilead Sciences compare to Amgen?

Summary

How does Gilead Sciences compare to Ligand Pharmaceuticals?

Summary

How does Gilead Sciences compare to Moderna?

Summary

How does Gilead Sciences compare to Regeneron Pharmaceuticals?

Summary

How does Gilead Sciences compare to Vir Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GILD vs. The Competition

Gilead Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gilead Sciences (GILD) Competitors

GILD vs. AMGN, LGND, MRNA, REGN, and VIR

How does Gilead Sciences compare to Amgen?

Do analysts recommend GILD or AMGN?

Which has higher valuation & earnings, GILD or AMGN?

Which has more volatility & risk, GILD or AMGN?

Does the media refer more to GILD or AMGN?

Is GILD or AMGN more profitable?

Do institutionals & insiders have more ownership in GILD or AMGN?

Is GILD or AMGN a better dividend stock?

Summary

How does Gilead Sciences compare to Ligand Pharmaceuticals?

Is LGND or GILD more profitable?

Which has more risk & volatility, LGND or GILD?

Which has stronger valuation & earnings, LGND or GILD?

Do analysts rate LGND or GILD?

Do institutionals and insiders hold more shares of LGND or GILD?

Does the media refer more to LGND or GILD?

Summary

How does Gilead Sciences compare to Moderna?

Do analysts prefer MRNA or GILD?

Which has more volatility & risk, MRNA or GILD?

Does the media favor MRNA or GILD?

Is MRNA or GILD more profitable?

Do institutionals & insiders believe in MRNA or GILD?

Which has better earnings and valuation, MRNA or GILD?

Summary

How does Gilead Sciences compare to Regeneron Pharmaceuticals?

Does the media prefer GILD or REGN?

Is GILD or REGN a better dividend stock?

Do insiders and institutionals hold more shares of GILD or REGN?

Which has better earnings and valuation, GILD or REGN?

Is GILD or REGN more profitable?

Which has more volatility & risk, GILD or REGN?

Do analysts recommend GILD or REGN?

Summary

How does Gilead Sciences compare to Vir Biotechnology?

Do analysts prefer GILD or VIR?

Do institutionals and insiders believe in GILD or VIR?

Which has more risk and volatility, GILD or VIR?

Which has better valuation & earnings, GILD or VIR?

Is GILD or VIR more profitable?

Does the media prefer GILD or VIR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GILD vs. The Competition

Gilead Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools